Management and follow-up for patients with advanced lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to explore the effectiveness of a patient process management platform in prolonging survival and improving the quality of life for individuals with locally advanced or metastatic non-small cell lung cancer (NSCLC). The study addresses the challenges faced by patients during treatment, including complications and adherence to medication regimens. By providing comprehensive follow-up and management, the study seeks to enhance patient compliance and alleviate psychological burdens associated with cancer treatment. The approach emphasizes the importance of continuous support and communication between healthcare providers and patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Fully understand the research and voluntarily sign the informed consent form (ICF)
2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form.
3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC).
4. According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC.
5. Not suitable for radical treatment or refuse surgery.
6. The life expectancy is not less than 3 months.
7. Be able to use a smartphone.

Exclusion Criteria:

1. Patients with mental illness.
2. Presence of any other malignant tumor.
3. Patients who are expected to undergo radical surgery.
4. Currently participating in clinical trials.
5. Subjects who judged by the investigator to be unsuitable to participate in the trial.

Where it's running

• The First Affiliated Hospital of Shandong First Medical University
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Jiandong ZHANG — Shandong First Medical University
• Study coordinator: Jiandong ZHANG
• Email: zhangjd165@sina.com
• Phone: (+86531)89268118

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant PD-L1/VEGF Bispecific Antibody with Chemo versus Chemo plus PD-1 Monoclonal Antibody in Locally Advanced NSCLC

  In people with locally advanced NSCLC, this study tests whether adding a PD-L1/VEGF bispecific antibody to chemotherapy before surgery improves outcomes compared with a PD-1 antibody added to chemotherapy.

  Recruiting at 2 sites Phase 3 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, China and 4 other locations · NCT07863999

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• Induction chemoimmunotherapy plus chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced NSCLC

  This trial tests induction chemoimmunotherapy followed by chemoradiotherapy and consolidation immunotherapy in adults with unresectable stage III NSCLC to see if it can improve outcomes compared with the standard PACIFIC approach.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai, Xuhui · NCT07632365

• Neoadjuvant SBRT then sintilimab with chemotherapy for N3-positive locally advanced NSCLC

  This approach tests whether focused radiation to the primary lung tumor followed by two cycles of sintilimab plus platinum-based chemotherapy before surgery can shrink N3-positive locally advanced non-small cell lung cancer and enable curative surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07309952

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.